International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"The comparison of fractional CO₂ laser and focused ultrasound for vulvar lichen sclerosus: a retrospective study.","authors":"Maoyu Liu, Xuerui Zhang, Linlin Xiao, Jing Liang, Dan Cheng, Yue Zhu, Shufang Chang","doi":"10.1080/02656736.2025.2507958","DOIUrl":"10.1080/02656736.2025.2507958","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the efficacy of fractional carbon dioxide laser (FxCO₂) and focused ultrasound (FUS) in treating vulvar lichen sclerosus (VLS).</p><p><strong>Methods: </strong>This single-center retrospective study included biopsy-proven VLS patients who did not respond to first-line topical corticosteroids and were treated with FxCO₂ or FUS as an alternative between January 2020 and October 2022. The efficacy was evaluated using the Cattaneo score and clinical scoring system (CSS). A subgroup analysis was conducted to compare efficacy based on VLS severity.</p><p><strong>Results: </strong>At the 3-month follow-up, the total effective rates were similar between FxCO₂ (91.18%, 31/34) and FUS (88.57%, 31/35) (<i>p</i> > 0.05). At the 6-month follow-up, the total effective rates for FxCO₂ decreased to 85.29% (29/34), while FUS remained at 88.57% (31/35) (<i>p</i> > 0.05). Recurrence rates were 14.7% (5/34) for FxCO₂ and 11.4% (4/35) for FUS (<i>p</i> > 0.05) at the 6-month follow-up. Although there was no significant difference in total CSS scores and clinician-administered sign scores between FxCO₂ and FUS at both follow-ups (<i>p</i> > 0.05), FxCO₂ suggested superior patient-administered symptom improvement at 3-month (median: FxCO₂ 3 vs. FUS 5, <i>p</i> < 0.05) and 6-month follow-ups (median: FxCO₂ 3 vs. FUS 5, <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>FxCO₂ and FUS show similar efficacy in treating VLS, with FxCO₂ suggesting a trend toward greater symptom relief. Further studies are needed to validate these preliminary observations.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2507958"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided percutaneous microwave ablation for locoregional recurrence of medullary thyroid carcinoma.","authors":"Isa Cam, Almotasem Shatat, Damla Köksalan, Said Atış, Ahmet Yalnız, Özgür Çakır, Alev Selek, Mehmet Sözen, Büşra Yaprak Bayrak, Seda Öztürk, Özge Telci Çakıllı, Nuh Zafer Cantürk, Ercüment Çiftçi","doi":"10.1080/02656736.2025.2533305","DOIUrl":"https://doi.org/10.1080/02656736.2025.2533305","url":null,"abstract":"<p><strong>Objective: </strong>Medullary thyroid carcinoma (MTC) is a rare, aggressive thyroid malignancy with frequent locoregional recurrence rate at 30-50%. Reoperative neck surgery is standard but challenging and risky. Ultrasound (US)-guided microwave ablation (MWA) offers minimally invasive alternatives, though evidence in recurrent MTC remains limited. This study evaluated the efficacy and safety of percutaneous US-guided MWA for treating recurrent MTC.</p><p><strong>Methods: </strong>A retrospective review included 22 patients with biopsy-proven locoregional recurrent MTC treated by US-guided percutaneous MWA after prior total thyroidectomy. All were either poor surgical candidates or declined reoperation. Thirty-four lesions underwent single-session outpatient ablation. Tumor size, serum calcitonin and volume reduction ratio (VRR) were assessed at baseline, 1, 3, 6 and 12 months post-ablation. Imaging and biochemical responses determined treatment outcomes. Recurrence-free survival between recurrent and non-recurrent groups was compared.</p><p><strong>Results: </strong>A total of 22 patients (median age 52 years; 14% hereditary) were included and MWA was successfully performed in all. Mean tumor diameter significantly reduced from 14.3 ± 11.6 mm to 2.6 ± 3.4 mm at 12 months (<i>p</i> < .001). Median serum calcitonin decreased significantly from 1165 pg/mL to 108 pg/mL at 12 months (<i>p</i> < .001). Treated lesions showed no regrowth; however, 50% developed new metastases elsewhere, correlating with higher initial metastatic burden (<i>p</i> = .001) and higher baseline calcitonin (<i>p</i> = .037).</p><p><strong>Conclusion: </strong>US-guided MWA effectively reduces tumor volume and calcitonin levels in recurrent MTC with minimal morbidity, though close surveillance for new metastases remains essential.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2533305"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High intensity focused ultrasound periosteal ablation in an animal model: potential for palliation of bone metastases.","authors":"Ron Aginsky, Suzanne Leblang, Eric Miller, Brian Skoglind, Abraham Nyska, Niv Rebhun, Michael Gofeld, Jean-Francois Aubry, Arik Hananel","doi":"10.1080/02656736.2025.2543330","DOIUrl":"https://doi.org/10.1080/02656736.2025.2543330","url":null,"abstract":"<p><strong>Purpose: </strong>Radiotherapy is standard-of-care for painful bone metastases yet has limitations and associated side effects. Ablation of sensory nerves endings along the periosteum with magnetic resonance imaging guided high intensity focused ultrasound (MRgFUS) proved safe and clinically effective for pain relief in patients with bone metastases, received FDA and CE approval, but has not gained widespread adoption due to significant cost and procedural and logistical complexity. This preclinical study evaluated the safety and feasibility of a fluoroscopy-guided high intensity focused ultrasound platform to ablate a targeted region along the surface of bones.</p><p><strong>Methods: </strong>Two healthy adult pigs received 6 kJ to 10 kJ sonications to the femur, ileum, and ribs. Animals were followed-up for 3 months. Longitudinal clinical observation and follow up magnetic resonance imaging (MRI), and computed tomography (CT) scans were performed. After sacrifice, the targeted bone and adjacent tissues were sent for histopathological evaluation to confirm thermal ablation.</p><p><strong>Results: </strong>Clinical observations revealed no neurological or musculoskeletal deficits. MRI scans on day 5 demonstrated robust ablation in all targeted sites. At 12 weeks, CT scans and histopathological evaluation showed complete healing of ablated regions.</p><p><strong>Conclusions: </strong>Periosteal bone ablation using the Neurolyser XR in a healthy porcine model is feasible with no adverse events, and no radiological or histological evidence of lasting injury or fracture to the targeted bones.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2543330"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144802441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights into FUNDC2P4 and HSF1 regulation of EMT in residual hepatocellular carcinoma following insufficient radiofrequency ablation.","authors":"Ni Tang, Liangxia Yang, Chengmou Huang, Lu Yang, Liangxing Yang, Haihang Zhang, Jiangzheng Zeng","doi":"10.1080/02656736.2025.2553210","DOIUrl":"https://doi.org/10.1080/02656736.2025.2553210","url":null,"abstract":"<p><strong>Objective: </strong>Insufficient radiofrequency ablation (IRFA) increases the risk of hepatocellular carcinoma (HCC) recurrence and metastasis. Our previous study revealed that IRFA downregulates FUNDC2P4 and promotes epithelial-mesenchymal transition (EMT), but the mechanisms remain unclear.</p><p><strong>Materials and methods: </strong>We simulated IRFA <i>in vitro</i> using a thermostatic water bath and assessed RNA and protein expression via qRT-PCR and Western blotting. Transcriptome analysis of LV-FUNDC2P4-transfected Huh7 cells, along with computational prediction, truncated mutants, and dual-luciferase assays, was performed to investigate the competitive binding of FUNDC2P4 and heat shock factor 1 (HSF1) to the Chromobox protein homolog 7 (CBX7) promoter. Functional assays, including CCK-8, Transwell, and wound-healing assays, evaluated cell proliferation, invasion, and migration.</p><p><strong>Results: </strong>IRFA induced EMT, downregulated FUNDC2P4, and upregulated HSF1. Gene set enrichment analysis indicated EMT suppression in Huh7 cells overexpressing FUNDC2P4. Overexpression of FUNDC2P4 increased CBX7 expression, while HSF1 overexpression reduced it. Co-transfection led to moderate CBX7 levels. Two overlapping binding sites within the CBX7 promoter were identified: the FUNDC2P4 triplex target site (nucleotides 1782-1832) and the HSF1 binding site (nucleotides 1790-1804). Functional studies suggest that FUNDC2P4 may compete with HSF1 to transcriptionally regulate CBX7, which in turn suppresses EMT and modulates HCC cell proliferation, invasion, and metastasis.</p><p><strong>Conclusion: </strong>These findings suggest a potential regulatory mechanism involving FUNDC2P4 and HSF1 that may contribute to HCC recurrence and metastasis after IRFA, warranting further <i>in vivo</i> and clinical investigation.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2553210"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies for adenomyosis before and after introducing USgHIFU in Shenzhen.","authors":"Yu Dai, Huang-Jin Luo, Yan Peng, Weichun Yang, Qiuling Shi, Ping Jin","doi":"10.1080/02656736.2025.2501244","DOIUrl":"10.1080/02656736.2025.2501244","url":null,"abstract":"<p><strong>Objective: </strong>To explore the impact of ultrasound-guided high-intensity focused ultrasound (USgHIFU) on patients with adenomyosis in Shenzhen and the changes in health economics.</p><p><strong>Design: </strong>A retrospective observational study.</p><p><strong>Setting: </strong>Hospitals.</p><p><strong>Patients: </strong>1093 patients with adenomyosis either treated with surgery or USgHIFU.</p><p><strong>Intervention(s): </strong>Surgical treatment and USgHIFU.</p><p><strong>Main outcome measure(s): </strong>Demographic information on the patients including age, education, marital status, job, fertility requirement and clinical characteristics such as fertility history, dysmenorrhea, degree of dysmenorrhea, hypermenorrhea, duration of dysmenorrhea, Numerical Rating Scale and history of cesarean section were recorded.</p><p><strong>Results: </strong>The overall trend in the number of patients with adenomyois was increasing after introduction. The average hospital stay of USgHIFU was decreasing year by year, and it was lowest among the three groups with below the total average length of hospitalization. The average cost of patients treated with USgHIFU was decreasing with the total earing for the hospital increasing. Compared to those with USgHIFU, patients selected hysterectomy are older (odds ratio [OR] = 1.17, 95% confidence interval [CI]: 1.13-1.21). However, patients undergoing hysterectomy have fewer symptoms of dysmenorrhea (OR = 0.31, 95% CI: 0.80-1.42) and tend to have lower educational levels. Patients selected adenomyomectomy tended to experience lower levels of dysmenorrhea (OR = 0.76, 95% CI: 0.60-0.93.</p><p><strong>Conclusion(s): </strong>USgHIFU reduces the cost and length of hospitalization for patients with adenomyosis and increases hospital revenue from these patients. It provides a suitable option for women with who have a strong desire to retain their uterus.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2501244"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automatic specific absorption rate (SAR) prediction for hyperthermia treatment planning using deep learning method.","authors":"Yankun Lang, Dario B Rodrigues, Lei Ren","doi":"10.1080/02656736.2025.2554860","DOIUrl":"10.1080/02656736.2025.2554860","url":null,"abstract":"<p><strong>Objective: </strong>To develop a deep learning method for fast and accurate prediction of Specific Absorption Rate (SAR) distributions in the human head to support real-time hyperthermia treatment planning (HTP) of brain cancer patients.</p><p><strong>Approach: </strong>We propose an encoder-decoder neural network with cross-attention blocks to predict SAR maps from brain electrical properties, tumor 3D isocenter coordinates and microwave antenna phase settings. A dataset of 201 simulations was generated using finite-element modeling by varying tissue properties, tumor positions, and antenna phases within a human head model equipped with a three-ring phased-array applicator. The model was trained and evaluated on this dataset using standard error metrics and structural similarity analysis.</p><p><strong>Main results: </strong>On a held-out test set of 20 samples, the model achieved a mean root-mean-squared error (RMSE) of 3.3 W/kg and a mean absolute error (MAE) of 1.6 W/kg across the whole brain. In target regions, RMSE and MAE were 4.8 and 2.5 W/kg, respectively. The structural similarity index (SSIM) reached a mean value of 0.90, and the computation time was reduced from 10 min (simulation-based) to 4 s using our deep learning approach. The proposed method enables accurate, efficient SAR prediction for HTP in the brain, potentially supporting real-time HTP to optimize tumor temperature and improve clinical outcomes.</p><p><strong>Significance: </strong>This work introduces a novel deep learning-based approach that significantly accelerates SAR calculation in HTP, enabling adaptive therapy strategies to improve treatment outcomes in hyperthermia.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2554860"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and risk factors for pelvic metastasis after microwave ablation of hepatocellular carcinoma: a nested case-control study.","authors":"Chao-Nan Chen, Chuan Pang, Fan Xiao, Zhen Wang, Jie Yu, Hui Feng, Ping Liang","doi":"10.1080/02656736.2025.2519350","DOIUrl":"https://doi.org/10.1080/02656736.2025.2519350","url":null,"abstract":"<p><strong>Background: </strong>Pelvic metastasis (PM) from hepatocellular carcinoma (HCC) remains understudied. Clarifying its risk factors after microwave ablation (MWA) is essential for optimizing surveillance strategies and guiding personalized management.</p><p><strong>Materials and methods: </strong>This retrospective study included patients with HCC who underwent MWA between January 2006 and August 2018. The cumulative rates of extrahepatic metastasis (EHM) and PM were estimated using the Kaplan-Meier method. Risk factors for EHM and PM were identified using the Cox proportional hazards model. A nested case-control design with a ratio of 1:4 was adopted, and the risk factors for PM were identified based on the logistic proportional hazards model.</p><p><strong>Results: </strong>A total of 1646 patients were included in this study, and 95 patients (19 cases and 76 controls) were included in the final case-control analysis. The 1-, 2-, 3-, and 5-year cumulative rates of EHM were < 20.0%, whereas those of PM were < 1.0%. Sex, Barcelona Clinic Liver Cancer stage, treatment-naïve HCC, number of HCC nodules, and platelet count were associated with EHM risk. Biopsy (<i>p</i> = 0.018) and Child-Pugh class (<i>p</i> = 0.004) were identified as factors associated with an increased risk of PM in the entire cohort. In this retrospective nested case-control study, Child-Pugh class (<i>p</i> = 0.027) and the number of biopsy punctures were associated with an increased risk of PM (<i>p</i> = 0.04).</p><p><strong>Conclusion: </strong>Multiple biopsy punctures and aggressive tumor features may indicate a high risk of PM.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519350"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of high-intensity focused ultrasound ablation for uterine fibroids with different blood flow grading based on Alder classification.","authors":"Lijun Yang, Jun Liu, Siyun Wu, Yanhua Han, Jin Bai, Qiuling Shi","doi":"10.1080/02656736.2025.2519346","DOIUrl":"10.1080/02656736.2025.2519346","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the efficacy of ultrasound-guided high-intensity focused ultrasound ablation (USgHIFU) for uterine fibroids with different blood flow grading based on Alder classification.</p><p><strong>Materials and methods: </strong>A total of 353 patients with solitary uterine fibroid who underwent USgHIFU from July 2014 to July 2019 were enrolled. The patients were classified as four groups based on blood flow grading in fibroids. The relevant factors influencing the therapeutic effect were analyzed.</p><p><strong>Results: </strong>Significant differences were observed in treatment time, irradiation time, irradiation intensity, nonperfusion volume (NPV), NPV ratio and energy efficiency factor (EEF) among the four groups (<i>p</i> < 0.05). As the level of blood flow increased, the treatment time, irradiation time, irradiation intensity and energy efficiency factor (EEF) of USgHIFU were increased, but the NPV ratio was decreased. No major complication occurred in any patient of the four groups. Overall, 318 patients completed long-term follow-up, and 55 of 318 patients underwent re-intervention (17.2%). Univariate analysis indicated that increased menstruation, uterine volume, type of fibroids, signal intensity on T2-weighted imaging, NPV ratio were factors related to reinterventin (<i>p</i> < 0.05). Multivariate analysis revealed that the type of fibroids and NPV ratio were independent risk factors for re-intervention (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Our results suggested that the difficulty of USgHIFU treatment for uterine fibroids could be evaluated using Alder classification. The fibroids with more blood flow were more difficulty to treat. However, satisfactory NPV ratio could be achieved even fibroids with abundant blood supply, and the long-term intervention rate was not increased.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519346"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of early MRI in assessing the risk of local tumor progression following irreversible electroporation for hepatocellular carcinoma treatment.","authors":"Lorenzo Carlo Pescatori, Mathilde Dessain, Gisèle N'Kontchou, Arthur Petit, Abou Diallo, Lorraine Blaise, Marie-Pierre Rols, Clair Poignard, Jean-Charles Nault, Nathalie Ganne-Carrié, Pierre Nahon, Olivier Sutter, Olivier Seror","doi":"10.1080/02656736.2025.2505595","DOIUrl":"10.1080/02656736.2025.2505595","url":null,"abstract":"<p><strong>Background: </strong>Irreversible electroporation (IRE) in hepatocellular carcinoma (HCC) triggers apoptosis instead of thermal coagulation, resulting in specific modifications within ablation zones. Aim of this study is to evaluate the diagnostic value of MRI performed three days post-IRE (D3MRI).</p><p><strong>Methods: </strong>This single-institution retrospective study examined patients with HCC treated by IRE from 2012-2017. Criteria included no prior HCC treatment, available D3MRI and one-month MRI (M1MRI) without residual tumor and at least one follow-up MRI after 3 months. We measured the peripheral hyperemia (IREPZ) and central necrotic zone (IRECZ) in the ablation area along with the minimum thickness of IREPZ (min.Th/IREPZ) on both D3MRI and M1MRI. The duration of follow-up and instances of local tumor progression (LTP) were recorded.</p><p><strong>Results: </strong>Forty-eight patients (median age: 68 years) with 65 treated nodules (median diameter: 19 mm) were included. The median follow-up was 37 months. D3MRI median dimensions were 67 mm for IREPZ, 19 mm for IRECZ, and 5 mm for min.Th/IREPZ. LTP occurred in 25 nodules after 18 months. 52% had LTP at min.Th/IREPZ. A min.Th/IREPZ ≤ 5 mm on D3MRI indicated a 24-fold higher risk of LTP (95% CI [2.25-255.95], <i>p</i> < .01), conversely, the min.Th/IREPZ on M1MRI had no predictive value.</p><p><strong>Conclusion: </strong>D3MRI appears to be a valuable tool for assessing the true ablation margins in HCC nodules treated with IRE and for identifying potential sites of local recurrence. It may, therefore, be considered for integration into the follow-up protocol for patients undergoing IRE treatment for HCC.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2505595"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.","authors":"Wenlong Yang, Xiaoyan Li, Xufang Tan","doi":"10.1080/02656736.2025.2524389","DOIUrl":"https://doi.org/10.1080/02656736.2025.2524389","url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency ablation (RFA) and microwave ablation (MWA) have been proven to be safe and effective methods for treating early-stage hepatocellular carcinoma (HCC). Although researchers have compared the efficacy of MWA and RFA, the results have not been consistent. Therefore, this study utilizes a large sample size and employs propensity score matching (PSM) combined with inverse probability weighting (IPW) to further investigate the effects between the two treatments.</p><p><strong>Methods: </strong>Patients with early-stage HCC who were diagnosed and treated with MWA or RFA between 2015 and 2022 were collected. The post-treatment effects and tumor outcomes were analyzed using PSM and IPW.</p><p><strong>Results: </strong>The 1-, 2- and 3-year recurrence rates were 40.89%, 68.07% and 84.13% for MWA, and 39.13%, 62.64% and 75.71% for RFA. The overall survival rates at 1, 2 and 3 years were 70.47%, 40.98% and 21.90% for MWA, and 70.53%, 44.85% and 30.60% for RFA. Cox regression indicated that age, tumor number and post-treatment were adverse prognostic factors for recurrence-free survival, while treatment method, age, tumor number and post-treatment were adverse prognostic factors for overall survival.</p><p><strong>Conclusion: </strong>The 5-year overall survival rates for RFA and MWA remained similar. The discrepancies in the 5-year cumulative recurrence-free rate might be attributed to the small MWA cohort, possible differences in patient selection, the margin assessment procedure used and the overall short follow-up period.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2524389"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}